Log in

NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

$4.57
-0.02 (-0.44 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.54
Now: $4.57
$4.78
50-Day Range
$4.07
MA: $4.33
$4.69
52-Week Range
$2.85
Now: $4.57
$7.21
Volume814,982 shs
Average Volume860,571 shs
Market Capitalization$461.25 million
P/E Ratio91.40
Dividend YieldN/A
Beta0.72
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Read More
BioDelivery Sciences International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.39 million
Cash Flow$0.18 per share
Book Value$0.84 per share

Profitability

Net Income$-15,310,000.00

Miscellaneous

Employees178
Market Cap$461.25 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$4.57
-0.02 (-0.44 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

How has BioDelivery Sciences International's stock been impacted by COVID-19 (Coronavirus)?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BDSI stock has increased by 15.4% and is now trading at $4.57.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioDelivery Sciences International
.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for BioDelivery Sciences International
.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings data on Wednesday, August, 5th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.03. The specialty pharmaceutical company had revenue of $36.58 million for the quarter, compared to analysts' expectations of $36.27 million. BioDelivery Sciences International had a net margin of 4.23% and a return on equity of 17.84%.
View BioDelivery Sciences International's earnings history
.

What price target have analysts set for BDSI?

9 analysts have issued 1 year price objectives for BioDelivery Sciences International's stock. Their forecasts range from $7.00 to $9.25. On average, they expect BioDelivery Sciences International's stock price to reach $8.46 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International
.

Has BioDelivery Sciences International been receiving favorable news coverage?

Headlines about BDSI stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about BioDelivery Sciences International
.

Are investors shorting BioDelivery Sciences International?

BioDelivery Sciences International saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,060,000 shares, an increase of 39.7% from the December 31st total of 2,190,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 3.7% of the shares of the stock are short sold.
View BioDelivery Sciences International's Short Interest
.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), NVIDIA (NVDA), Eldorado Gold (EGO), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Alibaba Group (BABA), Crispr Therapeutics (CRSP), JD.Com (JD) and Square (SQ).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Herm Cukier, CEO & Director (Age 54, Pay $599.46k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 55, Pay $410.71k)
  • Ms. Mary Theresa Coelho, CFO & Treasurer (Age 58, Pay $410.7k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $340.28k)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 59, Pay $377.89k)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by a variety of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (2.10%), Emerald Mutual Fund Advisers Trust (1.97%), Assenagon Asset Management S.A. (0.57%), Mackay Shields LLC (0.56%), Cadence Capital Management LLC (0.42%) and WINTON GROUP Ltd (0.40%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith.
View institutional ownership trends for BioDelivery Sciences International
.

Which institutional investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Aigen Investment Management LP, UBS Group AG, Searle & CO., Dupont Capital Management Corp, and NEXT Financial Group Inc. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith.
View insider buying and selling activity for BioDelivery Sciences International
.

Which institutional investors are buying BioDelivery Sciences International stock?

BDSI stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Russell Investments Group Ltd., MCF Advisors LLC, WINTON GROUP Ltd, Cadence Capital Management LLC, Emerald Mutual Fund Advisers Trust, Principal Financial Group Inc., and Quantitative Systematic Strategies LLC.
View insider buying and selling activity for BioDelivery Sciences International
.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $4.57.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $461.25 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.